Team:Heidelberg/Parts/Characterization

From 2010.igem.org

Revision as of 06:57, 27 October 2010 by Rebecca (Talk | contribs)

Characterization

parts

partconstructcommentsdesign
BBa_K337032tuning constructRSV-luc2, CMV-hRluc, SV40-shRNA miR
BBa_K337035tuning constructCMV-luc2, CMV-hRluc, SV40-shRNA miR
BBa_K337036tuning constructCMV-luc2, CMV-hRluc, RSV-shRNA miR
BBa_K337038tuning constructCMV TetO2-luc2, CMV-hRluc, RSV-shRNA miR
BBa_K337040tuning constructRSV-luc2, RSV-hRluc, SV40-shRNA miR
BBa_K337042tuning constructCMV-luc2, RSV-hRluc, SV40-shRNA miR
BBa_K337044tuning constructCMV-luc2, RSV-hRluc, RSV-shRNA miR
BBa_K337052shRNA miRhaat perfect binding siteKD:97%
BBa_K337053shRNA miRhaat imperfect binding site: point mut 11KD:69%
BBa_K337054shRNA miRhaat imperfect binding site: bulge 16-18KD:28%
BBa_K337055miR122 perfect binding siteKD:96%
BBa_K337056miR122 imperfect binding site:KD:64%
BBa_K337057miR122 imperfect binding site:KD:24%

experimental characterizations

Characterization of promoters in tuning constructs in T-Rex cells

Dual Luciferase Assay
In order to test for promoter efficiency and to check whether the miRNA kit assembly works fine 50ng of each construct with different promoter set-ups (table 1) were transfected into HEK 293 T-REx cells and other cell lines HEK, HeLa, Huh7 in 96-well plate format using FuGENE transfection reagent. As every construct is expressing firefly luciferase (luc2) and renilla luciferase (hRluc) at the same time the setup allows is unaffected by transfection efficiency and cell number. Each sample was transfected and measured by Dual luciferase assay in 8 replicates. As by this time no shRNA has been cloned into plasmid no knock-down of luc2 is expected and the different expression efficiencies allow for characterization of the different promoters. BBa_K337032 leads to a relative luciferase unit (RLU) of luc2 to hRluc expression of 6 RLU. BBa_K337035 and BBa_K337035 are showing a comparable expression of 12 - 13 RLU, which is in line with the knowledge that both luciferases are driven by the CMV promoter. Hek 293 T-Rex cells stably express the Tet repressor thus allows us to observe very efficient repression of Firefly luciferse expression if a CMV-TetO2 promoter is driving luc2 (BBa_K337038 and BBa_K337046). BBa_K337040 transfection into Hek T-Rex cells results in an expression of 15 RLU. BBa_K337042 and BBa_K337044 are constructed in a way that luc2 is driven by the CMV promoter and hRluc is driven by the RSV promoter and show a comparable expression of 17-20 RLU. This leads to the conclusion that the CMV promoter shows comparable expression to the RSV promoter in Hek T-Rex cell lines.

Table 1

partpromoter driving luc2 (Firefly)promoter driving (Renilla)promoter driving shRNA expression
BBa_K337032RSVCMVSV40
BBa_K337035CMVCMVSV40
BBa_K337036CMVCMVRSV
BBa_K337038CMV TetO2CMV RSV
BBa_K337040RSVRSVSV40
BBa_K337042CMVRSVSV40
BBa_K337044CMVRSVRSV
BBa_K337046CMV TetO2RSVRSV
Promoter strength characterization of tuning constructs in HEK 293 T-REx cell line



Characterization of BBa_K337035 and BBa_K337036 in different cell lines

Promoter strength characterization in different cell lines

If transfecting BBa_K337035 and BBa_K337036 are transfected into different cell lines it is obvious that Hek293T cells are the easiest to transfect with both constructs an expression of 17-22 RLU is to be measured. Hek T-Rex cells are showing and expression level of 12 RLU of both constructs. Hela cells are also showing constant expression levels of 8 RLU with both constructs. A rather low expression of 2RLU is to be seen by transfecting the 2 constructs in Huh7 cells. This might be due to low transfection efficiency of this cell line in general. All together it is to say that BBa_K337035 and BBa_K337036 show comparable expression.









characterization of part BBa_K337036

Regulation of gene expression can be achieved by fusing miRNA binding sites into the 3'UTR of a GOI. In case a referring shRNA miR is endogenously present or co-expressed, the GOI is knocked down. Strength of regulation thereby depends on binding site properties. We are able to tune gene expression linearly over a broad range. This is a first proof of principle for various miRNA-mRNA interaction in vitro. Therefore, we transfected HeLa cells in principle with our pSMB_miTuner Plasmid HD3 . It turned out, that no obvious effect of different binding sites on reporter gene expression could be measured (data not shown). We assume that the RSV promoter driving the shRNA miR is too weak for tight regulation of the referring binding site behind the GOI. Only if a sufficient amount of shRNA miR binds to its target, translation is significantly repressed. Thus, we expressed the shRNA miR from a separate plasmid which was always co-transfected with the original tuning construct. The reporter genes - i. e. Luc2 and hRluc - were also expressed from separate plasmids to get a reference as well as a transfection control. This was achieved by co-transfection the tuning construct with corresponding shRNA miRhaat and as a control a miRNA w/o binding sites in the target 3'UTR. The experiment was done in a 96-well plate by plating 5000 Hela cells/well 24h before transfection. Transfection was done using Fugene transfection reagent. 2.5ng of tuning construct were co-transfected with the shRNA miR construct of a concentration of 25 ng (1:10). Then, we conducted a Dual Luciferase Assay for quantification of gene expression. The data preciously shows a tuned expression from almost 0% to 100% (Fig. 1, Fig. 2). Lowest expression refers to complete knockdown through cloning of perfect binding sites into the 3'UTR to the reporter gene(always green bar on the left hand side of the figures). 100% refers to ordinary expression from a construct without binding sites (always orange column on the right hand side of the figures). In presence of the specific shRNA miR, gene expression was mediated to various levels through interactions with the different imperfect binding sites. Whereas, when an unspecific shRNA miR was expressed, gene expression remained unaffected (see raw data below). The latter aspect reveals, that the binding sites were correctly designed, since they seem to interact specifically with a referring shRNA miR. The constructs were tested in two different backbones: pBS_U6 and pBS_H1. Both are in viral context, meaning that they contain inverted terminal repeats (ITRs). The constructs can be packed into the capsid of an adeno-associated virus (AAV). We chose the data obtained by the construct with the U6 promoter as this promoter is more efficient than the H1 promoter, ensuring that the system is saturated and ensuring that the data is reproducible. The same constructs were also used for virus production to infect cells even more efficiently as compared to transfections. Because of the significant data, we decided to inject the viruses into mice to see the tuning effect also in vivo. The pBS_H1 construct should be used for mice injections since the expressed shRNA miR against human alpha-1-antitrypsine (hAAT) is cytotoxic in higher concentrations. The pBS_H1 backbone leads to moderate expression ranges, still obviously showing the tuning effect.

Figure 1: Tuning of gene expression through different imperfect shRNA miR binding sites in pBS_U6 Gene expression quantified via dual luciferase assay for M constructs containing different imperfect binding sites.
Figure 1: Tuning of gene expression through different imperfect shRNA miR binding sites in pBS_H1. Gene expression quantified via dual luciferase assay for M constructs containing different imperfect binding sites.

Strikingly, the order of constructs in terms of knockdown for the imperfect binding sites is similar. point mut 10 (1), point mut 10 (2) and point mut 11 (2) always show strong knockdown, whereas bulge 16-18, only seed and bulge 9-12(2) show only loose down-regulation. Consulting the binding site sequences, the weak knockdown can be addressed to bulges in the supplementary region or complete lack of the 3' region of the binding site. Still high strength could be maintained due to only single nucleotide exchanges in the central region of the binding site.